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Abstract
Dihydrofolate reductase (DHFR) is an essential enzyme that plays an important role in 
the production of cofactors that are required in deoxyribonucleic acid (DNA) synthesis. 
The literature suggests that DHFR is a potential drug target for the elimination of the 
parasitic worm, B. malayi. B. malayi is one of the causative parasites of lymphatic 
filariasis, a globally neglected tropical disease. In this study, we expressed and purified B. 
malayi DHFR. Expression was carried out in E. coli with a His6-tagged construct, and 
purification was achieved through affinity chromatography using a special strain of E. 
coli cells called “LOBSTR.” The resulting purified and active enzyme was used for 
steady-state kinetics characterization and inhibition studies. The catalytic activity, kcaU 
was found to be 1.4 ± 0.1s’1, the Michaelis Menten constant, Km, 14.7 ± 3.6pM for 
dihydrofolate, and the equilibrium dissociation constant, Kd, 22 ±0.0 lpM. B. malayi 
DHFR was compared to 13 other DHFR homologs in terms of ligand specificity 
determining residues; L. major, T. cruzi, T. bruci, and T. gondii exhibited the highest 
homology. Known inhibitors of these DHFR homologs were assayed with B. malayi 
DHFR and an inhibition profile was created for the enzyme. IC50 values were determined 
to be 0.0036 ± 0.0008 pM for methotrexate, 109 ± 34 pM for pyrimethamine, 32 ± 22 
pM for trimethoprim, 771 ± 4 4  pM for cycloguanil, >20,000 pM for 2,4- 
diaminopyrimidine, and 154 ± 46 pM for 2,4-diaminoquinazoline. These results provide 
the basis for the development of more potent and less toxic compounds that can inhibit B. 
malayi DHFR and help cure lymphatic filariasis.
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1. Introduction
1.1 Disease background
Lymphatic filariasis, also known as elephantiasis, is a neglected disease that 
affects more than 120 million people in 80 countries worldwide. This parasitic disease is 
caused by the nematodes W. bancrofti, B. timori, and B. malayi\ the latter is the focus of 
this research. The disease is transmitted by mosquitos that carry the infective stage 
larvae. Once the larvae enter the blood of a human host, they develop into adult female 
and male worms located in the lymphatic system. The lymphatic system damage caused 
by this parasite is especially detrimental to the infected population because the lymphatic 
system is an essential component of the immune system.19
Figure 1 & 2. B. malayi in a blood smear.
Lymphatic filariasis is associated with poverty; there is an ongoing need for more 
potent and economic drugs for the elimination of this disease. In 1997 the World Health 
Organization declared the disease as “eradicable” and in 2000 a program started with the 
purpose to eliminate the disease. This program has as its goals to stop transmission and 
control morbidity by administrating the combination of two sets of drugs,
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diethylcarbamazine citrate (DEC) and albendazole, or ivermectin and albendazole once a 
year for at least 5 years in areas prone to the occurrence of the disease. Two 
pharmaceutical companies, GlaxoSmithKline and Merck & Co. Inc. pledge to provide 
these drugs at no cost for as long as it takes to reach the set goals. Out of the 72 countries 
targeted by the program, so far only two countries, the Republic of Korea and China, 
have declared elephantiasis as no longer a threat to their population. In general, the 
progress seems to be going rather slow, a fact that can be attributed mostly to the 
prevalent ongoing need to understand the epidemiology of elimination of lymphatic 
filariasis.
1.2 Target overview
NA DP H + H +
NADP+
dihydrofolate tetrahydrofolate
Figure 3. Dihydrofolate is reduced to tetrahydrofolate by the enzyme dihydrofolate 
reductase (DHFR). DHFR catalyzes the transfer of a hydride from the cofactor NADPH, 
which in turns gets protonated.
Dihydrofolate reductase (DHFR) is a monomeric enzyme of about 20KDa that 
has been evolutionarily well conserved. It catalyzes the reaction from dihydrofolate to 
tetrahydrofolate in the presence of NADPH. Tetrahydrofolate is a precursor of cofactors
2
necessary for the synthesis of purines, pyrimidines, and many amino acids, which are 
necessary for cell proliferation and growth.
Figure 4. 3D structure of E. coli DHFR. NADPH is shown in green and DHF is shown in 
magenta.
DHFR is a therapeutic target for infectious diseases.15 Antifolates are a specific 
group of compounds that inhibit DHFR; the group includes anticancer, antibacterial and 
antimalarial drugs. DHFR inhibition by these antifolate compounds is mediated through 
the disruption of DNA biosynthesis and it is the basis of chemotherapeutic action.7 The 
evaluation of synthetic antifolate agents, biguanide and dihydrotriazine, along with the 
drugs pyrimethamine and trimethoprim, has demonstrated that DHFR inhibitors could be 
promising molecules for the treatment of B. malayi? Furthermore, the evaluation of 12 
diverse antifolate compounds with 2,4-diaminopyrimidine and 2,4-diamino-s-triazine
3
structural features against B. malayi proves that DHFR inhibitors are indeed novel drug 
candidates against lymphatic filariasis.16 However, these studies were done on B. malayi, 
not on the target; the purified RraDHFR. Encouragement came from these findings to 
purify 5mDHFR and prove that the target can be inhibited with antifolate compounds, as 
predicted.
1.3 Project goals
1.3.1 Previous work (by Karla Sanchez)
The first goal of this project was to express and purify B. malayi DHFR for the 
first time. Before I joined this project, graduate student Karla Sanchez obtained the amino 
acid sequence of 5mDHFR from UniProt (A8QGA9) and engineered a His6-tag at the N- 
terminus. The purpose of the His6-tag is to enable the capture of the protein by nickel or 
cobalt ions on the specific resin used for purification.1 The designed DNA-sequence was 
then codon optimized for expression in E. coli (Genewiz) and the resulting 5raDHFR 
DNA fragment was subcloned into the pET25b expression vector. At this point the 
project ran into some difficulties when Z?mDHFR did not exhibit any catalytic activity.
Dr. Goodey, Dr. Gubler, and Karla worked hard to fix this issue, and they realized that 
the problem came from the amino acid sequence of the enzyme. There are two different 
fimDHFR sequences on UniProt, one of them (A8QGA9) was entered on August 2014 
and was missing 13 amino acids (residues 113-125) essential for the folding of the 
protein; which will be referred to as the loop mutant or Ain.^RmDHFR from hereon. 
After the right sequence was obtained from UnitProt (A8QBG1, entered on March 2015), 
the same process previously explained was carried out on the full sequence and Z?raDHFR 
exhibited catalytic activity.
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Figure 5. Ni-NTA resin interacting with polyhistidine tag.
1.3.2 My goals
Once I joined this project, the first challenge was to purify B. malayi DHFR, 
which had been expressed in BL21 (DE3) E. coli cells. The subsequent affinity 
chromatography purification yielded impure protein (<95%). It was speculated that the 
impurity most likely represented (a) contaminating histidine-rich E. coli protein(s) when 
using Ni-NTA affinity chromatography. Dr. Ueli Gubler suggested to introduce our 
pET25n-RraDHFR plasmid into a recently described special E. coli expression strain, 
BL21 (DE3) derivative, called “LOBSTR” (low background strain). The LOBSTR strain 
is specifically engineered to eliminate the most abundant contaminants caused by His- 
mediated purification.1 The approach works by lowering the background contamination 
due to ArnA (74 KDa) and SlyD (21 KDa), bifunctional enzymes involved in the 
modification of lipid A phosphates with aminoarabinose and a peptidyl-prolyl cis/trans- 
isomerase, respectively.1 When recombinant protein expression is low, the protein starts 
competing with endogeneous ArnA and SlyD for binding to the Ni or Co resin, leading to 
the co-purification of ArnA and SlyD as impurities. The LOBSTR strain genomically 
modifies ArnA and SlyD by mutagenizing them to change the surface-expose His to Ser.
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These modifications reduce the Ni and Co binding affinity of the unwanted host 
proteins.1
Kinetic characterization and enzyme inhibition studies followed the expression 
and purification of RraDHFR. Kinetic parameters like Km and kcat serve as a comparison 
between different DHFRs from different organisms. The dissociation constant KD serves 
as a comparison between the loop mutant and the wildtype in terms of the binding of the 
cofactor NADPH and the consequent folding of the protein. RraDHFR is expected to bind 
with a greater affinity than An3_i25#raDHFR.
In order to complete an inhibition profile for the enzyme, it was necessary to 
make predictions of antifolate compounds that could potentially inhibit Z?raDHFR. A 
novel phylogenetics-based method for predicting residues involved in inhibitor 
specificity in the DHFR family identified eighteen amino acid positions in thirteen DHFR 
homologs that are involved in ligand specificity (inhibitor binding).5 With this 
information at hand, and by extensive alignments of the 13 DHFR homologs with B. 
malayi DHFR, the 18 amino acid positions predicted to be involved in inhibitor 
specificity were determined in the BmDHFR sequence. The DHFR homologs with the 
highest percentage identity to the 18 amino acid residues in BmDHFR were L. major, T. 
cruzi, T. gondii, and T. bruci. Known DHFR inhibitors of these organisms were predicted 
to also inhibit our enzyme and were obtained to generate an inhibition profile for B. 
malayi DHFR.
6
2. Methods and Materials
2.1. BmDHFR expression
BL21(DE3) or LOBSTR (Kerafast) cells were transformed with isolated pET25b- 
RraDHFR DNA and expression of RmDHFR was explored at room temperature and 30 
°C. BL21(DE3) and LOBSTR transformants were grown in LB/amp (lOOug/ml 
ampicillin) to an OD600 ~0.6 at 37 °C. Cultures were allowed to reach the desired 
expression temperatures and expression was induced with 0.3 mM IPTG. Cells were 
harvested after 5 hours and overnight. To extract soluble protein, cells were harvested by 
centrifugation at 5,000 rpm for 30 min, resuspended in ~15 mL of Equilibration Buffer 
(20 mM sodium phosphate, 300 mM NaCl (PBS), 10 mM imidazole, pH 7.4) and lysed 
by sonication for 4 min (output: 5, duty cycle: 10, W-225 Heat Systems Ultrasonics 
sonicator with microtip). Cell debris and soluble protein extract were separated by 
centrifugation at 5,000 rpm for 30 minutes (Beckman Coulter Avanti J-26S XP centrifuge 
with JA-10 rotor).
2.2. Purification of BmDHFR
Soluble cell lysate was loaded onto HisPur™ Ni-NTA Resin (Thermo Scientific) 
equilibrated in a gravity-flow column with Equilibration Buffer (20 mM sodium 
phosphate, 300 mM NaCl (PBS), 10 mM imidazole, pH 7.4). The resin was washed with 
Wash Buffer (PBS, 25 mM imidazole, pH 7.4) and RmDHFR was eluted with Elution 
Buffer (PBS, 250 mM imidazole, pH 7.4). Wash and elution fractions were monitored for 
protein content by a microtiter-plate based Bradford assay.
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2.3. BmDHFR activity assay
ÆraDHFR activity was determined with saturating concentrations of NADPH and 
DHF (100 |iM each) by measuring the change in absorbance at 340 nm. The differential 
extinction coefficient value of 13.2 mM 'em 1 (for the combination of conversion of 
NADPH to NADP+ and DHF to THF) was used to convert the change in absorbance over 
time to an initial velocity. In a typical experiment, (reaction volume of 200 pi) RmDHFR 
(45 to 85 nM) was incubated with NADPH (100 pM) for 2-3 min, adding DHF to a final 
concentration of 100 pM, and recording the absorbance at 340 nm for 3 minutes. All 
experiments were carried out in MTEN buffer (50 mM 2-morpholinoethane sulphonic 
acid (MES), 25 mM Tris, 25 mM ethanolamine, and 100 mM NaCl). The assays were 
completed in triplicate at 25 °C in a SpectraMax M3 microplate reader. The optimum pH 
for the DHFR reaction was determined by comparing the rate of change in absorbance at 
pH values ranging from 4 to 10 in one unit increments. Turnover number (&cat) was
y
calculated using the formula /cca  ^= max at pH 6.00.
2.4. Determination of the Michaelis-Menten constant (KM)
The affinity of RraDHFR for its substrate DHF was determined by measuring the 
enzyme activity as a function of increasing concentrations of DHF. The concentration of 
DHF in the well ranged from 0.13 to 100 pM; dilutions were made in MTEN pH 6.0. 
NADPH (100 pM) and 46 nM enzyme were incubated for 2-3 min, DHF was added to 
initiate the reaction, and absorbance was recorded at 340 nm. As above, all experiments 
were completed at 25 °C in MTEN at pH 6.0 in a reaction volume of 200 pi. Initial
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velocity was plotted as a function of DHF concentration using Kaleidagraph and the data 
was fitted to the Michaelis-Menten equation. Assays were completed in triplicate.
2.5. Prediction of BmDHFR Inhibitors
Previous research predicted that 18 amino acid positions in 13 selected DHFR 
homologs would play a role in enzyme in inhibition.5 The 18 residues were identified in 
RmDHFR by aligning its entire sequence with the sequences of the 13 homologues in 
MEGA software. The unwanted amino acid residues were deleted from each of the 14 
sequences using MEGA software, leaving the sequences with only the desired 18 amino 
acid positions. An individual alignment was done between the 18 residues of Bm and 
each of the 13 homologs; the percent alignment identity was recorded. A literature search 
was conducted with the top 4 homologous DHFR proteins having the highest percent 
identity to Bm DHFR. The drugs that inhibit those 4 homologs were predicted to also 
inhibit Bm DHFR and were subsequently used for inhibition studies.
2.6. Effects of DMSO concentration on RraDHFR activity.
Stock solutions of predicted RraDHFR inhibitors were prepared in DMSO. 
Control experiments with DMSO were conducted to confirm that DMSO at the relevant 
concentrations did not affect 5mDHFR activity. The assay was set up the same way, with 
concentrations of 100 pM and 46 nM for NADPH and Z?raDHFR respectively. 15 ul 
DMSO stocks resulting in concentrations ranging from 18% to 75% were included in the 
assay as replacement for the inhibitors. The final concentration of DMSO in the 
inhibitions assays was always below 3 % in all experiments meaning the activity of
9
RraDHFR was not be affected by the inclusion of DMSO; DMSO did not inhibit 
RmDHFR.
2.7. Inhibition Studies
Methotrexate (MTX, Sigma M9929), pyrimethamine (PMT, Fluka 46706), 2,4- 
diaminopyrimidine (Sigma 468231), 2,4-diaminoquinazoline (Sigma CDS001152), 
trimethoprim (TMP, MP Biomedicals 0910013), and cycloguanil (CYC, Cayman 16861) 
were evaluated as inhibitors of RraDHFR catalytic activity. Stock solutions were prepared 
in DMSO and dilutions of all stock solutions were made in MTEN pH 6.0. RraDHFR 
activity was measured as described above, with varying concentrations of inhibitor 
added. NADPH (100 pM) and 5raDHFR (46 nM) in a total volume of 200 pi were 
incubated with 15 pi inhibitor (varying concentrations in different wells) for 2-3 minutes 
before the reaction was initiated by adding DHF (final concentration 20 pM, final 
reaction volume 200 ul). Percent activity for each inhibitor concentration was obtained by 
dividing the rate from the inhibition experiment by the rate of the control experiment 
where no inhibitor was added. Dose response curves were generated in Kaleidagraph. 
Data was fitted to the Hill equation.
% response = min response + (max response -  min response)/^ +
with n = -1. IC50 values for each inhibitor were calculated. All assays were completed in 
triplicate.
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2.8. Determination of equilibrium dissociation constant
The thermodynamic dissociation constant (KD) for the binding of NADPH to
5mDHFR and An3_i255mDHFR was determined by monitoring the tryptophan 
fluorescence (ex. 290 nm/em. 340 nm) as NADPH was added to 228 nM enzyme 
(wildtype) and 172 nM (An3.i25#mDHFR) in MTEN, pH 6.0 at room temperature. The 
NADPH concentration ranged from 0 to 1.4 mM.
3. Results and Discussion
3.1. Expression and purification of recombinant #mDHFR
Based on the UniProt database amino acid sequence A8G6A9, the DNA sequence 
coding for RmDHFR was designed to incorporate an N-terminal His6-tag. The sequence 
was codon optimized for expression in E. coli (Genewiz) and the resulting 5raDHFR 
DNA fragment was subcloned into the pET25b expression vector. This pET25b- 
RraDHFR plasmid was introduced into the BL21(DE3) derivative, “LOBSTR”.1 Several 
small-scale expression studies revealed that soluble RmDHFR protein expression could 
be obtained by induction with 0.3 mM IPTG at room temperature for 24 hours.
For larger scale purification, soluble protein was derived from an induced 250 mL 
culture by sonication and centrifugation, and the resulting supernatant was applied to a 
standard Ni-NTA affinity column. Purification of the soluble, recombinant RraDHFR can 
be completed through this single step if expression is performed in the “LOBSTR” 
expression strain. SDS-PAGE analysis of the eluate showed that the enzyme had the 
expected size of approximately 22 kDa, consistent with the predicted molecular weight of 
22.086 kDa calculated from the DNA sequence (Figure 7). Expression and purification
11
via this method yielded ~1.8 mg purified 5mDHFR/L of induced culture. Concentration 
of RraDHFR was 46 nM. However, when expression was carried out in the standard 
BL21(DE3) strain, followed by Ni-NTA chromatography of soluble protein, a -66 kDa 
contaminant remained in the eluted protein fractions (Figure 6).
Figure 6. SDS-PAGE analysis of 5raDHFR expression and purification in the BL21 
(DE3) E. coli expression strain. The Ni-NTA column one step purification resulted in 
<95% pure protein due to the histidine-rich host proteins that were co-purified. Lane 1. 
Ladder (Fisher Bioreagents EZ-Run Protein Standard BP3600); Lane 2. Flow-through; 
Lane 3. Wash; Lanes 4-8. Elution fractions from the Ni-NTA column.
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Figure 7. SDS-PAGE analysis of Z?mDHFR expression and purification in the LOBSTR 
E. coli expression strain. The Ni-NTA column one step purification resulted in >95 % 
pure protein. Lane 1. Ladder (Fisher Bioreagents EZ-Run Protein Standard BP3600); 
Lane 2. Flow-through; Lane 3. Wash; Lanes 4-7. Four separate elution (1 mL each) 
fractions from the Ni-NTA column.
3.2. BmDHFR activity assay
After the expression and purification of BmDHFR, the next step was the make 
sure the enzyme had catalytic activity. This was tested on a 96-well plate reader using 
different concentrations of enzyme until there was an evident decrease in absorbance, i.e.
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a slope in the plot of absorbance vs. time at a wavelength of 340nm. The concentrations
of DHF and NADPH were 100 pM each and RraDHFR was 46 nM.
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Figure 8. 5raDHFR catalytic activity with saturating concentrations of NADPH and DHF 
(100 pM each) and concentration of RraDHFR of 46 nM. Change in absorbance was 
measure at 340nm over 10 minutes. The differential extinction coefficient value of 13.2 
mM 'cm'1 (for the combination of conversion of NADPH to NADP+ and DHF to THF) 
was used to convert the change in absorbance over time to an initial velocity.
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3.3. Kinetic Characterization of BmDHFR
The dependence of the catalytic activity on pH was explored; catalytic activity was found 
to be highest at pH ~ 6.0 (Figure 10). The &cat value for RraDHFR was determined at pH 
6.0 to be 1.4 ± 0.1s'1 (Figure 9) and the for DHF 14.7 ± 3.6 pM (Figure 11).
y = -0.0008x+0.8208
Figure 9. A representative graph of three trials of kca{ measurements at a wavelength of 
340nm. This experiment was carried out in a spectrophotometer using a 1 mL plastic 
cuvette as oppose to the other experiments that were conducted in a 96-well plate 
spectrophometer. The enzyme concentration in the assay was 78.6 nM. The average of 
the three individual trials gave a kcal of 1.4 ± 0.1s'1.
Sample of calculation of kca{:
AC slope 0.0008
time £Xl (13.2mM ^ cm 1)(lc?n)(s) 0.0000606mMs 1
15
Kcat =
0.0000606mMs 1 
0.0000393mM 1.542s 1
pH
Figure 10. Dependence of catalytic activity of BmDHFR on pH. Individual experiments 
were conducted in a 96-well plate at room temperature with 100 pM NAPDH, 100 pM 
DHF and 46 nM BmDHFR. The buffer used was MTEN (1250mM MES, 125mM Tris, 
125mM ethanolamine, 500mM NaCl) with pH ranging from 5.5 to 12. The reported data 
is an average of duplicate measurements.
16
60
Figure 11. Steady-state kinetic analysis of BmDHFR gives a KM value for DHF of 14.7 ± 
3.6 pM and a Vmax value of 57 ± 14 nM*s_1 (n=3). The data shown is representative for 
one out three experiments. Rate of change of absorbance at 340 nm was measured as a 
function of DHF concentration with 100 pM NADPH and 0.045 pM BmDHFR at pH 6.0 
at room temperature. Michaelis-Menten curves were generated in KaleidaGraph and
-l
report initial velocity (mM*s ) versus [DHF] (pM).
3.4. Prediction of inhibitor profile against BmDHFR using PAn Predictor
We used a variation of the previously published computational approach (“PAn 
Predictor”) to predict antifolate compounds that might serve as effective inhibitors of 
B/nDHFR.5 First, we aligned the 13 DHFR homolog sequences used originally to predict 
inhibitor specificity determinants in the DHFR family with BmDHFR and identified the
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18 residues in RraDHFR corresponding to the 18 amino acid positions that are inhibitor 
specificity determinants in the DHFR family.5 These positions in RmDHFR are Val5, 
Glyl2, Met27, Asn44, Ala45, Lys51, Phe60, Val84, Phe89 Leu95, Leu96, Glyl33, 
Alal37, Vall39, Phel40, Phel41 and Glul69 (Figure 12). The RraDHFR residue 
corresponding to the putative catalytic acid (Asp 27) in E. coli DHFR is Glu26 (indicated 
by # in Figure 12). The requirement for the Glu26 to be in the protonated state may 
correspond with the sharp decrease in activity as the pH increases shown in Figure 10.
* * * *
BmDHFR ....MNLIVA VDGCGGIGRN GGMPW.FLPA EMARFAKLTT LTMDSGKKNA 45
HsDHFR MVGSLNCIVA VSQNMGIGKN GDLPWPPLRN EFRYFQRMTT TSSVEGKQNL 50
EcDHFR ...MISLIAA LAVDRVIGME NAMPW.NLPA DLAWFKRNTL  NKP 39
*  *  *
IPPKFRPLKN RFNWLSRKI KEESNENWV ARSFESAISL 95
IPEKNRPLKG RINLVLSREL KEPPQGAHFL SRSLDDALKL 100
I...GRPXPG RKNIILSSQ. .PGTDDRVTW VKSVDEAIAA 84
*  *
BmDHFR VIMGRKVWES 
HsDHFR VIMGKKTWFS 
EcDHFR VIMGRHTWES
* ★ ★ ★ ★ ★ ★  
BmDHFR LQDME... NI ETIWNIGGRE VYELGLNSPF LHQMYITRVE GDFLADVFFP 142 
HsDHFR TEQPELANKV DMVWIVGGSS VYKEAMNHPG HLKLFVTRIM QDFESDTFFP 160 
EcDHFR AG..... DV PEIMVIGGGR VYEQFL. .PK AQKLYLTHID AEVEGDTHFP 126
BmDHFR EVDYGRFI.K 
HsDHFR EIDLEKYK.L 
EcDHFR DYEPDDWESV
*
STES....EE MHEEKGIKYR YEIYTVKIDK VA 179 
LPEYPGVLSD VQEEKGIKYK FEVY....EK ND 187 
FSEF....HD ADAQNSHSYS FEIL....ER R. 159
Figure 12. Alignment of ÆraDHFR sequence with H. sapiens and E. coli DHFRs. The 18 
amino acid positions that are predicted as inhibitor specificity determinants in the DHFR
family are identified by bold letters. These 18 residues were identified in H. sapiens and 
E. coli DHFRs by previously published approach PAn Predictor, and in RraDHFR by an 
alignment with the 13 DHFR homologs, including Hs and Ec.5 The catalytic residue
Asp27 is labeled on the E. coli sequence (#) and the corresponding Glul7 is labeled on
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the B. malayi sequence (|). (Howell et al. 1986) The horizontal rectangle is showing the 
loop mutant on the B. malayi sequence.
We then determined the percentage identity between RmDHFR and other DHFR 
sequences based on only these 18 specificity determining residues. This analysis showed 
that DHFR sequences from L. major and T. cruzi had the highest homologies (>70%) to 
RraDHFR (Table 1).
Entry Organism Set 1 Set 2 Set 3
P07382 Lm 72.2% 72.2% 66.6%
Q27793 Tc 72.2% 61.1% 61.1%
Q27783 Tb 66.6% 55.5% 55.5%
Q07422 Tg 66.6% 55.5% 55.5%
P16184 Pc 61.1% 61.1% 55.5%
002604 Pv 50.0% 50.0% 44.4%
P13922 p f 50.0% 44.4% 44.4%
P00374 Hs 44.4% 50.0% 44.4%
Q920D2 Rn 44.4% 50.0% 44.4%
P9WNX1 Mt 16.6% 16.6% 11.1%
P0ABQ4 Ec 11.1% 22.2% 11.1%
030463 Ma 11.1% 11.1% 11.1%
P00381 Lc 5.5% 16.6% 5.5%
Table 1. Highest to lowest percentage identity of 13 organisms to RraDHFR. Sets 1, 2, 
and 3 consist of 15, 15, and 12 amino acid positions, respectively.5 In every set, each 
DHFR homolog sequence was aligned with 5raDHFR and the percentage identity was 
determined. At the top of the list is the organism, L. major DHFR, which was the most 
similar to RraDHFR based on the 18 specificity-determining residues. The inhibitors were
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then selected based on this information and by doing a literature search of the drugs that 
inhibit the top 4 organisms with the highest percent identity to RraDHFR.
A subsequent literature search and examination of BindingDB (Liu, T 2007) 
allowed us to identify a set of six known DHFR inhibitors that inhibit DHFRs with high 
homology to ÆmDHFR in terms of the 18 residues studied. The IC50 values of these six 
compounds against RraDHFR were determined.
Drugs
Inhibition
Activity
DHFR
homolog
IC50
(uM) Ki (uM)
Ki
reference
article
IC50
reference
article
Pyrimethamine weak L. m ajor 0.25
Gilbert,
2002
Trimethoprim weak L. m ajor -16.5 0.12
Gilbert,
2002
White, et al. 
2004
Cycloguanil weak
L. m ajor 0.011 5.8uM
Gilbert,
2002
Basco, et al. 
1994
Methotrexate potent
T. cruzi -0.0083 3.8X10'5
Gilbert,
2002
White, et al. 
2004
2,4-
Diaminopyrimidine potent
L.m ajor/T.
gondii/T.
cruzi 0.2 0.0078
Pez, et al. 
2003
Pez, et al. 
2003
2,4-
Diaminoquinazoline potent L. m ajor 0.2 0.0070
Khabnadide 
h, et al. 2005
Khabnadide 
h, et al. 2005
Table 2. Known drugs that bind the DHFR homolog sequences with the highest 
percentage identity to BmDUFR. The drugs exhibiting potent inhibition activity, low 
IC50’s and Ki’s were selected to be acquired for further studies.
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3.5. Effects of DMSO concentration on 5raDHFR activity.
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Figure 13. Z?mDHFR activity at concentrations of DMSO ranging from 18% to 75% 
(stock) and 1.4% to 5.6% (in assay). Graph shows that the enzyme retained its catalytic 
activity when assayed in various concentrations of DMSO instead of the inhibitor, 
proving that DMSO does not alter the inhibition studies results. Individual experiments 
were conducted in a 96-well plate at room temperature with conditions in the well of 100 
pM NAPDH, 100 pM DHF and 46 nM RmDHFR. Percent activity was obtained by 
calculating the slope of the line (abs. at different cone, of DMSO vs. time) over the slope 
of the line (abs. with no DMSO vs. time) times 100%.
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3.6. Inhibition by antifolate compounds
Determination of IC50 values of six antifolate compounds against recombinant 
RmDHFR showed that methotrexate was the most potent inhibitor of the six compounds 
tested against BmDHFR with an IC50 value of 4.0 ± 0.8 nM (Table 3). Pyrimethamine, 
trimethoprim, cycloguanil, and 2,4-diaminoquinazoline were found to inhibit RraDHFR 
with IC50 values of 109 ± 34, 32 ± 22, 771± 44 and 154 ± 46 pM, respectively (Tables 4-
7). The inhibitor 2,4-diaminopyrimidine did not inhibit RraDHFR at concentrations below 
20 mM.
3.6.1. Methotrexate
Inhibition curve, IC50 and Ki determination:
Concentration (nM)
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Figure 14. A representative graph of a B. malayi DHFR inhibition curve in the presence 
of the inhibitor Methotrexate. The average of three trials gave an IC50 of 0.0040 ± 
0.0008pM. Individual experiments were conducted in a 96-well plate at room 
temperature with conditions in the well of 100 pM NAPDH, 100 pM DHF and 46 nM 
fimDHFR. Percent activity in the y-axis was determined by dividing the slope of the abs. 
of methotrexate at different concentrations vs. time over the slope of the assay (abs. vs. 
time) with no inhibitor, and multiplying by 100%.
MTX IC50 (pM) Ki (pM)
Trial 1 0.0032998 0.001397898
Trial 2 0.0030152 0.001277333
Trial 3 0.0045142 0.001912356
Average 0.003609733 0.001529195
Std. dev. 0.000796112 0.000337258
Average ± Std. dev. 0.004 ± 0.0008 0.002 ± 0.0003
Table 3. IC50 and Ki from three trials of Methotrexate.
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3.6.2. Pyrimethamine
Inhibition curve, IC50 and K] determination:
Concentration (microM)
Figure 15. A representative graph of one of three separate trials of a B. malayi DHFR 
inhibition experiment carried out in the presence of the inhibitor Pyrimethamine. Data fit 
using KaleidaGraph. Individual experiments were conducted in a 96-well plate at room 
temperature with conditions in the well of 100 pM NAPDH, 100 pM DHF and 46 nM 
Z?raDHFR. The average of the three trials gave an IC50 of 90.2 ± 7.9pM. Percent activity 
in the y-axis was determined by dividing the slope of the abs. of pyrimethamine at 
different concentrations vs. time over the slope of the assay (abs. vs. time) with no 
inhibitor, and multiplying by 100%.
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PMT IC50 (]iM) K, (|iM)
Trial 1 98.354 41.66581556
Trial 2 82.497 34.94829683
Trial 3 147.38 62.43475504
Average 109.4103333 46.34962248
Std. dev. 33.82503219 14.3293364
Average ± Std. dev. 109 ± 34 46 ± 14
Table 4. IC50 and Ki from three trials of Pyrimethamine.
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3.6.3. Trimethoprim
Inhibition curve, IC50 and K] determination:
Concentration (uM)
Figure 16. A representative graph of a B. malayi DHFR inhibition curve established in 
the presence of the inhibitor Trimethoprim. Data fit using KaleidaGraph. The average of 
three trials gave an IC50 of 31.8 ± 5.4pM. Individual experiments were conducted in a 
96-well plate at room temperature with conditions in the well of 100 pM NAPDH, 100 
pM DHF and 46 nM RraDHFR. Percent activity in the y-axis was determined by dividing 
the slope of the abs. of trimethoprim at different concentrations vs. time over the slope of 
the assay (abs. vs. time) with no inhibitor, and multiplying by 100%.
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T M P IC 50 OiM) K i(n M )
Trial 1 15.44 6.541
Trial 2 22.65 9.595
Trial 3 57.32 24.28
Average 31.80333333 13.472
Std. dev. 22.39020396 9.483742774
Average ± Std. dev. 32 ±22 13 ± 9
Table 5. IC50 and Ki from three trials of Trimethoprim.
27
3.6.4. Cycloguanil
Inhibition curve, IC50 and Ki determination:
Concentration (uM)
Figure 17. A representative graph of a B. malayi DHFR inhibition curve established in 
the presence of the inhibitor Cycloguanil. Data fit using KaleidaGraph. The average of 
three trials gave an IC50 of 770.6 ± 534pM. Individual experiments were conducted in a 
96-well plate at room temperature with conditions in the well of 100 pM NAPDH, 100 
pM DHF and 46 nM 5mDHFR. Percent activity in the y-axis was determined by dividing 
the slope of the abs. of cycloguanil at different concentrations vs. time over the slope of 
the assay (abs. vs. time) with no inhibitor, and multiplying by 100%.
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CYC IC50 (nM) Ki OiM)
Trial 1 719.44 428.1687449
Trial 2 796.99 474.3219838
Trial 3 795.42 473.3876113
Average 770.6166667 458.6261134
Std. dev. 44.32724482 26.38099186
Average ± Std. dev. 771 ±44 459 ± 26
Table 6. IC50 and Ki from three trials of Cycloguanil.
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3.6.5. 2,4-Diaminoquinazoline 
Inhibition curve, IC50 and Ki determination:
Concentration (mM)
Figure 18. A representative graph of a B. malayi DHFR inhibition curve established in 
the presence of the inhibitor 2,4-Diaminoquinazoline. Data fit using KaleidaGraph. The 
average of three trials gave an IC50 of 192.9 ± 88.0pM. Individual experiments were 
conducted in a 96-well plate at room temperature with conditions in the well of 100 pM 
NAPDH, 100 pM DHF and 46 nM 5mDHFR. Percent activity in the y-axis was 
determined by dividing the slope of the abs. of 2,4-diaminoquinazoline at different 
concentrations vs. time over the slope of the assay (abs. vs. time) with no inhibitor, and 
multiplying by 100%.
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2,4-Diaminoquinazoline IC50 (pM) Ki (pM)
Trial 1 137.89 58.41449568
Trial 2 117.72 49.86985591
Trial 3 205.66 87.12397695
Average 153.7566667 65.13610951
Std. dev. 46.06706235 19.5154414
Average ± Std. dev. 154 ±46 65 ±20
Table 7. IC50 and Ki from three trials of Cycloguanil.
3.7. Comparing experimental IC50 values in Table 8 for B. malayi DHFR to predictions
Compound IC50(hM) Ki(pM)
Methotrexate 0.004 ± 0.0008 0.002 ± 0.0003
Pyrimethamine 109 ±34 46 ± 14
Trimethoprim 32 ±22 13 ±9
Cycloguanil 771 ±44 459 ± 26
2,4-Diaminopyrimidine >20,000 >8,472
2,4-Diaminoquinazoline 154 ±46 65 ±20
Table 8. Summary of IC50 and Kj values for a set of antifolate compounds tested against 
RraDHFR. Values are averages of at least triplicate experiments and standard deviations 
are shown. The experiments were conducted at pH 6.0, at room temperature, with 100 
pM NADPH, 100 pM DHF, and 46 nM DHFR. The Kj values were obtained using the 
Cheng Prusoff equation (Prusoff 1973).
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The predicted inhibitors’ IC50 values from the literature are given in Table 1; they 
represent the values obtained for the DHFR homologs most similar to B. malayi DHFR in 
terms of the amino acid positions predicted to play a role in enzyme inhibition.5 A 
comparison of the experimental to the expected values showed that the IC50’s for 
methotrexate and trimethoprim were closest to the predictions. Methotrexate was 
confirmed to be the strongest inhibitor for B. malayi DHFR, this did not surprise because 
based on its close homology to L. major DHFR. However, IC50 values for other 
inhibitors like cycloguanil, pyrimethamine, and 2,4-diaminoquinazoline were not close to 
the predictions; they are considered weak inhibitors. They were expected to be better 
inhibitors based on the prediction from Table 1 showing that these compounds inhibit L. 
major with more potency. Notably, 2,4-diaminopyrimidine was determined not to be an 
inhibitor of B. malayi DHFR, despite the predictions and its similarity to 2,4- 
diaminoquinazoline. These findings suggest that perhaps a compound with a higher 
resemblance to the structure of 2,4-diaminoquinazoline could be a possible inhibitor for 
B. malayi DHFR. The extra ring in the 2,4-diaminoquinazoline structure could play a role 
in the inhibition of the DHFR enzyme. In conclusion, with varying potencies all 
compounds except for 2,4-diaminopyrimidine inhibited Z?mDHFR, as it was expected.
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3.8. Dissociation Constants for NADPH of Mutant and Wildtype B. malayi DHFR
[NADPH] (mM)
1 106
Figure 18. Dissociation constant (K d) analysis of NADPH in the presence of the mutant 
(A) and wildtype (B) of B. malayi DHFR. Both graphs above are representative of three 
separate trials. Concentration of enzyme and NAPDH were ~200nM and 0 to 1.4 mM, 
respectively. The wavelength was at 340nm. The average for the mutant KD was 129 ± 38 
pM and the average for the wildtype KD was 22 ±14 pM.
Based on the KD data we can conclude that An3.i255wDHFR binds NADPH with 
a lower affinity than BtiiDHFR. However, these findings suggest that the mutant enzyme 
is still able to fold to some extent. It can also be concluded that the 13 amino acids 
missing from the mutant enzyme are located on the pF-pG loop, by comparison with E. 
coli DHFR. In E. coli DHFR this loop plays a role in dynamics associated with catalysis, 
therefore we suggest that the pF~pG loop also plays the same role in RwDHFR.
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4. Summary
In summary, I expressed and purified the target enzyme, DHFR, in the B. malayi 
organism using a special strain of E. coli cells, LOBSTR, and an Ni-NTA affinity 
chromatography. The enzymatic characterization of B. malayi DHFR was carried out 
using the purified protein. The Michaelis-Menten constant, Km, was found to be 14.7 ± 
3.6pM, which shows that the enzyme has high affinity for the substrate. The turnover 
number, kcaU and the equilibrium dissociation constant, KD, for NADPH was found to be
1.4 ± 0.1s'1 and 22 ±0.0 lpM, respectively. The inhibition studies showed that 
methotrexate was the strongest inhibitor. However, methotrexate is used for 
chemotherapy and is an immunosuppressant, a fact that makes it unsuitable for the 
treatment of lymphatic filariasis in human patients. Trimethoprim ranks second after 
methotrexate in IC50 and Ki value, suggesting that perhaps it can be a lead compound in 
the search for a more potent and less toxic drug. Obtaining the crystal structure of 
BmDHFR in the presence and absence of a high affinity inhibitor is the obvious next step 
to be undertaken, in order for organic chemists to have a good understanding of the 
binding site of the enzyme and be able to work on optimizing existing compounds to fit 
in the active site while keeping toxicity and side effects to a minimum. The present 
project thus might serve as the basis for the discovery of a potent compound that will 
hopefully make it to the market to help cure this neglected disease that affects millions of 
unprivileged people.
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